Introduction {#H1-1-ZOI180102}
============

Increasing access to essential medicines is integral to the effort to reduce global morbidity and mortality.^[@zoi180102r1]^ While access and health outcomes have generally improved in recent decades, these efforts face a serious obstacle from the threat of substandard and falsified (SF) medicines.^[@zoi180102r2],[@zoi180102r3],[@zoi180102r4]^ Poor-quality medicines increase risks of morbidity and mortality by prolonging illnesses and heighten the risk of treatment failure, poisoning, and adverse drug interactions.^[@zoi180102r5],[@zoi180102r6]^ Circulation of SF medicines with little clinical effectiveness also places entire communities at risk of drug resistance, posing a threat to global treatment effectiveness, as well as undermining people's overall trust in the health system and its legitimate health care professionals.^[@zoi180102r5],[@zoi180102r6],[@zoi180102r7],[@zoi180102r8],[@zoi180102r9]^ Over time, diminished trust in licensed health care professionals may further encourage informal care-seeking and self-medication.^[@zoi180102r10]^ Poor health outcomes can also erode trust in the manufacturers of genuine pharmaceutical products, which are often challenging to distinguish from SF ones without the use of verification technologies.^[@zoi180102r11]^

The risks posed by these medicines extend beyond health outcomes.^[@zoi180102r6]^ Poor-quality medicines cause increased costs for patients and the health system.^[@zoi180102r5],[@zoi180102r6]^ Some of these costs, such as resources wasted on ineffective therapies and treating additional complications, are borne primarily by consumers and health facilities.^[@zoi180102r5],[@zoi180102r6]^ Others, such as decreased economic productivity resulting from prolonged illness, reduced sales and tax revenue, and costs of anticounterfeiting initiatives, are borne by governments, companies, the pharmaceutical industry, donors, and society as a whole.^[@zoi180102r5],[@zoi180102r6],[@zoi180102r12]^ Furthermore, SF medicines purchased through the use of personal savings, sale of assets, or borrowing can lead people into poverty.^[@zoi180102r5]^

Substandard and falsified medicines are a complex but critical global health issue.^[@zoi180102r3],[@zoi180102r5],[@zoi180102r6],[@zoi180102r9]^ The World Health Organization (WHO) estimates that 10.5% of medicines worldwide are substandard or falsified.^[@zoi180102r5]^ Furthermore, most of the burden falls on low- and middle-income countries (LMICs) because of poor pharmaceutical governance, weak technical capacity, and poor supply-chain management.^[@zoi180102r6],[@zoi180102r13]^ Until recently, the efforts to combat SF medicines have been fragmented because of the complexity of the issue and intellectual property rights disputes.^[@zoi180102r14]^ In 2017, in an effort to draw the issue away from intellectual property rights and reframe it solely as a public health issue, the World Health Assembly officially adopted the term *substandard and falsified* to replace the previous term, *substandard/spurious/falsely labeled/falsified/counterfeit (SSFFC).*^[@zoi180102r15]^ Substandard medicines are officially defined as "authorized medical products that fail to meet either their quality standards or specification, or both" and may result through poor manufacturing, shipping or storage conditions, or when the drug is sold beyond the expiration date.^[@zoi180102r14]^ Falsified medicines are defined as "medical products that deliberately/fraudulently misrepresent their identity, composition or source."^[@zoi180102r14]^

This issue not only has significant health and economic consequences, but directly threatens global health security and efforts to meet the United Nations Sustainable Development Goal 3.8, to achieve universal access to safe and effective essential medicines.^[@zoi180102r1],[@zoi180102r5]^ Despite this, the full extent of the problem is unclear.^[@zoi180102r5],[@zoi180102r6]^ Furthermore, research efforts to examine the issue have often faced poor methodological quality and exhibited high amounts of variability.^[@zoi180102r16]^ To address these issues, we systematically reviewed and analyzed the existing evidence to assess the prevalence and estimated economic burden of SF essential medicines across LMICs.

Methods {#H1-2-ZOI180102}
=======

For this systematic review and meta-analysis, 5 databases were searched: PubMed, EconLit, Global Health, Embase, and Scopus. A research librarian was consulted to aid in the creation of 2 separate searches and ensure all relevant studies were identified. The first search used terms related to "substandard and falsified medicines" (incorporating SSFFC terms) and the second, "quality of medicine." Both searches were run with terms associated with "low- and middle-income countries." Additional articles were incorporated through systematic searches of the WHO Essential Medicines and Health Products Information Portal,^[@zoi180102r17]^ the United States Pharmacopeial Convention Medicines Quality Database,^[@zoi180102r18]^ publications in the Worldwide Antimalarial Resistance Network database,^[@zoi180102r19]^ and references of included articles and pertinent literature reviews.^[@zoi180102r3],[@zoi180102r5],[@zoi180102r20],[@zoi180102r21],[@zoi180102r22],[@zoi180102r23],[@zoi180102r24],[@zoi180102r25],[@zoi180102r26],[@zoi180102r27],[@zoi180102r28],[@zoi180102r29]^ The comprehensive search strategy and terminology as well as a list of additional sources searched are presented in eAppendix 1 in the [Supplement](#note-ZOI180102-1-s){ref-type="supplementary-material"}. This systematic review and meta-analysis is registered in the PROSPERO database and is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses ([PRISMA](http://www.equator-network.org/reporting-guidelines/prisma/)) reporting guidelines. Institutional review board approval was not required as this study did not involve human subjects research.

The primary eligibility criteria for this systematic review were that the article examined the quality of essential medicines, the prevalence of SF medicines, and/or the economic impact of SF medicines. Economic impact is defined broadly as any economic estimate associated with the manufacture, trade, sale, or consumption of SF medicines. Peer-reviewed articles in English, Chinese, French, Portuguese, Spanish, or German published before November 3, 2017, were included in the review. All study locations not in LMICs, as classified as the World Bank at the time of review, were excluded. Abstract-only publications, correspondence without data, studies of medicines that are not classified as essential medicines by the WHO,^[@zoi180102r30]^ case reports, and publications that did not include sample sizes of tested medicines were also excluded.

All unique articles were independently assessed by 3 of us (D.G.H., S.B., and D.R.E.) based on title and abstract. Those marked for inclusion, or whose title and abstract were not sufficient to determine inclusion, were then reviewed using the full text. Any discrepancies between reviewers were resolved by a third party (S.O.). Full-text records were sought and obtained through the library systems of 3 major US research universities. Selected articles were then categorized into 1 or both of 2 groups: (1) primary prevalence studies and/or (2) articles containing an estimate of economic impact.

Four of us (D.G.H., S.B., S.K.L., and D.R.E.) independently conducted the data extraction with oversight by a third party (S.O.). Data describing prevalence, type of medicines, country setting, and sample size were extracted from all included primary prevalence studies. Studies were grouped according to the following categories: type of medicines tested, sample size, continent, and year of publication.

Studies including an estimate of economic impact were compiled separately and data were extracted on estimate source, period of analysis, geographic scope, target medicine, and estimated economic impact. Citation mining was conducted to determine the root sources of the cited statistics. For every estimate of economic impact, we noted the root source, type of literature, and methods used, or recorded that the root source was untraceable if it could not be traced back.

The meta-analysis of the prevalence of SF medicines focused on studies that tested 50 samples or more and adequately reported sampling and testing methods to ensure the rigor of prevalence estimates. Studies that did not report primary data, included previously reported data, or included data from regulatory laboratories that only tested suspected medicines were excluded from the meta-analysis. Where available, uncertainty ranges or minimum to maximum prevalence were noted alongside summary statistics. Mean prevalence across studies---weighted by sample size and Medicine Quality Assessment Reporting Guidelines (MEDQUARG) score^[@zoi180102r16]^ using a random-effects model---was determined overall and by world region. Mean weighted prevalence was also assessed across subcategorizations of 8 study characteristics: sample size, publication year, sampling method, purchasing method, chemical analysis, chemical testing method, conflict of interest, and MEDQUARG score. The prevalence for each subcategorization was compared with the overall prevalence with a 1-sample *t* test and with the subgroup gold standard by an unequal variances *t* test. Overall uncertainty ranges were estimated using a 95% confidence interval based on the calculated standard deviation.

Additional data were extracted for these studies in the meta-analysis, including methods of sampling, purchasing, and pharmaceutical quality analysis. Sampling methods were categorized as random, convenience, survey-based, or not specified; purchasing method was categorized by use of mystery clients, using overt methods, or not specified; and pharmaceutical quality analysis was categorized by the specific chemical analyses. Additionally, each study was assessed to determine whether it (1) examined the actual presence of active pharmaceutical ingredients (APIs), (2) assessed the quantity or percentage of the APIs, and/or (3) looked for other ingredients (excipients and other analytes). Use of Raman spectrometry, any mention of impurities, or highlighting unknown peaks in chromatographs were counted as searching for other ingredients.

To assess the quality of the studies included in the meta-analysis, studies were independently examined by 2 of us (D.R.E. and S.K.L.) according to MEDQUARG.^[@zoi180102r16]^ Each study was assigned a 12-point MEDQUARG score adapted by Almuzaini and colleagues^[@zoi180102r20]^ with scores of 6 or greater being considered acceptable quality. The interrater reliability was assessed between the 2 reviewers and, where possible, the original Almuzaini scores using the Spearman ρ. Additional information about the MEDQUARG scoring metric, this study's reported MEDQUARG scores (eTable 1 in the [Supplement](#note-ZOI180102-1-s){ref-type="supplementary-material"}), and results of the interrater reliability assessments are presented in eAppendix 2 in the [Supplement](#note-ZOI180102-1-s){ref-type="supplementary-material"}. Additionally, studies included in the meta-analysis were analyzed for potential conflict of interest by examining the articles' author statements, funding source, and/or institutional affiliations for a direct partisan or industry relationship. Studies with a description of funding source with no apparent partisan or industry affiliation were considered free of potential conflict of interest. Other studies that did not include a funding source and had no discernable industry author affiliations were categorized as unclear.

Study heterogeneity was evaluated using a random-effects model and reported using the Cochran *Q* and *I*^2^. Publication bias was evaluated using a funnel plot analysis (eFigure 1 in the [Supplement](#note-ZOI180102-1-s){ref-type="supplementary-material"}) with a regression test for funnel plot asymmetry. Baujaut and influence plot analyses (eFigures 2 and 3 in the [Supplement](#note-ZOI180102-1-s){ref-type="supplementary-material"}) were conducted to examine which articles contributed the most heterogeneity. A mixed-effects model was used to test for potential modifiers. The results of these analyses are included in eAppendix 3 in the [Supplement](#note-ZOI180102-1-s){ref-type="supplementary-material"}. All analyses were made using R statistical software version 3.3.2 (R Project for Statistical Computing).^[@zoi180102r31]^

Results {#H1-3-ZOI180102}
=======

Systematic Review {#H2-1-ZOI180102}
-----------------

Our searches yielded a total of 4284 citations, of which 3164 were unique and screened based on title and abstract. The full text was assessed for 754 articles. We identified 265 primary data collection studies that sought to determine the prevalence of SF essential medicines in LMICs ([Figure 1](#zoi180102f1){ref-type="fig"}). Studies not included in the meta-analysis are shown in eReferences 1 in the [Supplement](#note-ZOI180102-1-s){ref-type="supplementary-material"}.

![PRISMA Flowchart](jamanetwopen-1-e181662-g001){#zoi180102f1}

Globally, data on SF medicines in LMICs came primarily from articles focused on Africa (133 studies \[50.2%\]) and Asia (90 studies \[34.0%\]). Eight studies (3.0%) covered countries in South America, while 3 studies (1.1%) tested samples from each of Europe, North America, and Oceania. Twenty-five studies (9.4%) tested samples from multiple continents. More than half of the 265 prevalence studies (157 \[59.2%\]) were published in this decade (2010-present) with 63 (23.8%) published in the last 3 years (2015-2017). Antimalarials (117 studies \[44.2%\]) and antibiotics (104 studies \[39.2%\]) were the most commonly examined medicines, including 35 studies (13.2%) that investigated both. The total number of samples tested was 400 647, with a median (interquartile range) study sample size of 41 (10-242) (see eTable 2 in the [Supplement](#note-ZOI180102-1-s){ref-type="supplementary-material"} for additional details on study characteristics).

Meta-analysis {#H2-2-ZOI180102}
-------------

Our meta-analysis included a subset of 96 studies^[@zoi180102r32],[@zoi180102r33],[@zoi180102r34],[@zoi180102r35],[@zoi180102r36],[@zoi180102r37],[@zoi180102r38],[@zoi180102r39],[@zoi180102r40],[@zoi180102r41],[@zoi180102r42],[@zoi180102r43],[@zoi180102r44],[@zoi180102r45],[@zoi180102r46],[@zoi180102r47],[@zoi180102r48],[@zoi180102r49],[@zoi180102r50],[@zoi180102r51],[@zoi180102r52],[@zoi180102r53],[@zoi180102r54],[@zoi180102r55],[@zoi180102r56],[@zoi180102r57],[@zoi180102r58],[@zoi180102r59],[@zoi180102r60],[@zoi180102r61],[@zoi180102r62],[@zoi180102r63],[@zoi180102r64],[@zoi180102r65],[@zoi180102r66],[@zoi180102r67],[@zoi180102r68],[@zoi180102r69],[@zoi180102r70],[@zoi180102r71],[@zoi180102r72],[@zoi180102r73],[@zoi180102r74],[@zoi180102r75],[@zoi180102r76],[@zoi180102r77],[@zoi180102r78],[@zoi180102r79],[@zoi180102r80],[@zoi180102r81],[@zoi180102r82],[@zoi180102r83],[@zoi180102r84],[@zoi180102r85],[@zoi180102r86],[@zoi180102r87],[@zoi180102r88],[@zoi180102r89],[@zoi180102r90],[@zoi180102r91],[@zoi180102r92],[@zoi180102r93],[@zoi180102r94],[@zoi180102r95],[@zoi180102r96],[@zoi180102r97],[@zoi180102r98],[@zoi180102r99],[@zoi180102r100],[@zoi180102r101],[@zoi180102r102],[@zoi180102r103],[@zoi180102r104],[@zoi180102r105],[@zoi180102r106],[@zoi180102r107],[@zoi180102r108],[@zoi180102r109],[@zoi180102r110],[@zoi180102r111],[@zoi180102r112],[@zoi180102r113],[@zoi180102r114],[@zoi180102r115],[@zoi180102r116],[@zoi180102r117],[@zoi180102r118],[@zoi180102r119],[@zoi180102r120],[@zoi180102r121],[@zoi180102r122],[@zoi180102r123],[@zoi180102r124],[@zoi180102r125],[@zoi180102r126],[@zoi180102r127]^ (67 839 drug samples) that met inclusion criteria. [Figure 2](#zoi180102f2){ref-type="fig"} shows the results of the meta-analysis of the prevalences grouped by region and medication category. The average overall prevalence of SF medicines was 13.6% across LMICs (95% CI, 11.0%-16.3%). Regional prevalence estimates ranged from 18.7% in Africa (95% CI, 12.9%-24.5%) to 13.7% in Asia (95% CI, 8.2%-19.1%) and 14.4% (95% CI, 0%-33.2%) for other single-region studies. Studies that tested samples across multiple continents observed a lower average prevalence, with a pooled prevalence of 11.6% (95% CI, 5.8%-17.5%). The average prevalence of SF medicines was 19.1% (95% CI, 15.0%-23.3%) for antimalarials and 12.4% (95% CI, 7.1%-17.7%) for antibiotics. [Table 1](#zoi180102t1){ref-type="table"} presents the data extracted from these studies grouped by medication class. A map of the calculated national prevalence of SF medicines is presented in [Figure 3](#zoi180102f3){ref-type="fig"} (eFigures 4-7 in the [Supplement](#note-ZOI180102-1-s){ref-type="supplementary-material"} present the reported prevalence of SF medicines by each study in the meta-analysis grouped by region).

![Prevalence of Substandard and Falsified Medicines in Low- and Middle-Income Countries by Medicine Category and Region\
The forest plot presents mean prevalence by study category among studies that only examined specific medicines.](jamanetwopen-1-e181662-g002){#zoi180102f2}

###### Studies on the Prevalence of Substandard and Falsified Medicines by Medication Type

  Source                                                                                                         Countries                                                                                                                                                                             Samples, No.   Substandard and Falsified Medicines, % (95% CI)   Sampling Method               Purchasing Method       Testing Method                                                                                                               Tested % Active Pharmaceutical Ingredient   Tested Other Ingredients
  -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- ------------------------------------------------- ----------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- --------------------------
  **Antibiotics**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Bate et al,^[@zoi180102r39]^ 2012                                                                              Angola, Brazil, China, Democratic Republic of the Congo, Egypt, Ethiopia, Ghana, India, Kenya, Mozambique, Nigeria, Russia, Rwanda, Tanzania, Thailand, Turkey, Uganda, Zambia        1437           4.95 (4.1-5.8)                                    Random                        Mystery client          GPHF-Minilab[^a^](#zoi180102t1n1){ref-type="table-fn"}                                                                       Yes                                         NS
  Bate et al,^[@zoi180102r41]^ 2014[^c^](#zoi180102t1n3){ref-type="table-fn"}                                    Angola, Democratic Republic of the Congo, Egypt, Ethiopia, Ghana, Kenya, Nigeria, Rwanda, Tanzania, Uganda, Zambia, India, Thailand, China, Turkey, Russia, Brazil, Mozambique        1470           5.45 (3.9-7)                                      Random                        Mystery client          GPHF-Minilab[^a^](#zoi180102t1n1){ref-type="table-fn"}                                                                       Yes                                         NS
  Bate et al,^[@zoi180102r40]^ 2015                                                                              Angola, Democratic Republic of the Congo, Egypt, Ethiopia, Ghana, Kenya, Nigeria, Rwanda, Tanzania, Uganda, Zambia, India, Thailand, China, Turkey, Russia, Brazil, Mozambique        1437           9.88                                              Random                        Mystery client          GPHF-Minilab[^a^](#zoi180102t1n1){ref-type="table-fn"}                                                                       Yes                                         NS
  Hadi et al,^[@zoi180102r52]^ 2010                                                                              Indonesia                                                                                                                                                                             104            18                                                Convenience                   Mystery client          HPLC                                                                                                                         Yes                                         NS
  Khan et al,^[@zoi180102r64]^ 2013                                                                              India                                                                                                                                                                                 59             33.9                                              Random                        Mystery client          Visual examination, HPLC, UV, dissolution, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                   Yes                                         NS
  Kitutu; Uganda Medicines Transparency Alliance,^[@zoi180102r114]^ 2015                                         Uganda                                                                                                                                                                                179            14                                                Random                        NS                      GPHF-Minilab[^a^](#zoi180102t1n1){ref-type="table-fn"}                                                                       Yes                                         NS
  Khurelbat et al,^[@zoi180102r68]^ 2014[^c^](#zoi180102t1n3){ref-type="table-fn"}                               Mongolia                                                                                                                                                                              1236           14.64 (13.2-17.8)                                 Random                        Mystery client          Disintegration, dissolution, TLC, UV, IR, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                    Yes                                         NS
  Kyriacos et al,^[@zoi180102r70]^ 2008                                                                          Lebanon, Jordan, Egypt, Saudi Arabia                                                                                                                                                  111            56                                                Random                        NS                      HPLC                                                                                                                         Yes                                         NS
  Nabirova et al,^[@zoi180102r77]^ 2017                                                                          Kazakhstan                                                                                                                                                                            854            19.1                                              Random                        NS                      GPHF-Minilab[^a^](#zoi180102t1n1){ref-type="table-fn"}                                                                       Yes                                         Yes
  Nazerali and Hogerzeil,^[@zoi180102r78]^ 1998[^c^](#zoi180102t1n3){ref-type="table-fn"}                        Zimbabwe                                                                                                                                                                              840            16                                                Convenience                   NS                      Disintegration, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                              Yes                                         NS
  Obaid et al,^[@zoi180102r81]^ 2009                                                                             Pakistan                                                                                                                                                                              96             15.6                                              Random                        NS                      HPLC                                                                                                                         Yes                                         NS
  Okumura et al,^[@zoi180102r85]^ 2010                                                                           Cambodia                                                                                                                                                                              254            8.7                                               Convenience                   NS                      Dissolution                                                                                                                  No                                          No
  Patel et al,^[@zoi180102r88]^ 2012[^c^](#zoi180102t1n3){ref-type="table-fn"}                                   South Africa                                                                                                                                                                          135            8.9                                               Convenience                   Overt                   Visual inspection, dissolution, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                              Yes                                         Yes
  Ramachandran et al,^[@zoi180102r94]^ 2013[^c^](#zoi180102t1n3){ref-type="table-fn"}                            India                                                                                                                                                                                 1948           8.5                                               Convenience                   NS                      Other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                                              Yes                                         NS
  Rookkapan et al,^[@zoi180102r96]^ 2005                                                                         Thailand                                                                                                                                                                              198            25.3                                              Random                        Overt                   HPLC, UV, dissolution                                                                                                        Yes                                         NS
  Sabartova et al,^[@zoi180102r98]^ 2011                                                                         Armenia, Azerbaijan, Belarus, Estonia, Kazakhstan, Latvia, Moldova, Ukraine, Uzbekistan                                                                                               291            11.3                                              Convenience                   NS                      Visual inspection, dissolution, HPLC, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                        Yes                                         Yes
  Wafula et al,^[@zoi180102r117]^ 2016[^c^](#zoi180102t1n3){ref-type="table-fn"}                                 Kenya                                                                                                                                                                                 60             17                                                Convenience                   Mystery client          HPLC, dissolution, disintegration, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                           Yes                                         NS
  Yoshida et al,^[@zoi180102r127]^ 2014[^c^](#zoi180102t1n3){ref-type="table-fn"}                                Cambodia                                                                                                                                                                              325            14.5                                              Random                        Mystery client          HPLC, UV, dissolution, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                       Yes                                         NS
  Yusuf et al^[@zoi180102r118]^ 2011[^c^](#zoi180102t1n3){ref-type="table-fn"}                                   Afghanistan                                                                                                                                                                           348            9.5                                               Convenience                   Overt                   Other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                                              NS                                          NS
  **Antimalarials**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Abdo-Rabbo et al,^[@zoi180102r32]^ 2005                                                                        Yemen                                                                                                                                                                                 50             28                                                Random, convenience           NS                      Dissolution, HPLC, UV                                                                                                        Yes                                         NS
  ACT Consortium,^[@zoi180102r33]^ 2015                                                                          Tanzania                                                                                                                                                                              1737           4.1                                               Random                        Overt                   HPLC, MS, UV                                                                                                                 Yes                                         NS
  Amin et al,^[@zoi180102r34]^ 2005                                                                              Kenya                                                                                                                                                                                 116            39.15 (33-45.3)                                   Convenience                   Overt                   Dissolution, HPLC, UV                                                                                                        Yes                                         NS
  Basco,^[@zoi180102r37]^ 2004                                                                                   Cameroon                                                                                                                                                                              284            39.44 (12-74)                                     NS                            Mystery client          Colorimetry, TLC                                                                                                             Yes                                         Yes
  Bjorkman et al,^[@zoi180102r43]^ 2012                                                                          Uganda                                                                                                                                                                                558            19.4                                              Random                        Mystery client          Raman spectrometry, visual inspection                                                                                        Yes                                         Yes
  Chikowe et al,^[@zoi180102r46]^ 2015                                                                           Malawi                                                                                                                                                                                112            88.4                                              Random, convenience           Mystery client, overt   Visual inspection, colorimetry, TLC, HPLC                                                                                    Yes                                         NS
  Dondorp et al,^[@zoi180102r47]^ 2004                                                                           Myanmar, Lao People's Democratic Republic, Vietnam, Cambodia, Thailand                                                                                                                232            44.4 (9-53)                                       Convenience                   Mystery client          Colorimetry, HPLC, UV                                                                                                        Yes                                         NS
  Evans et al,^[@zoi180102r48]^ 2012                                                                             Guyana, Suriname                                                                                                                                                                      135            70.4                                              Convenience                   Mystery client, overt   Visual inspection, dissolution, disintegration, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                              No                                          NS
  Gimenez et al,^[@zoi180102r50]^ 1997                                                                           Cambodia                                                                                                                                                                              128            28                                                Convenience                   Mystery client          TLC, dissolution, HPLC, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                      Yes                                         NS
  Guo et al,^[@zoi180102r51]^ 2017                                                                               Myanmar                                                                                                                                                                               153            0.7                                               Convenience                   NS                      Colorimetry, HPLC                                                                                                            Yes                                         NS
  Idowu et al,^[@zoi180102r56]^ 2006                                                                             Nigeria                                                                                                                                                                               50             38                                                NS                            NS                      Visual inspection, colorimetry                                                                                               No                                          NS
  Ioset and Kaur,^[@zoi180102r57]^ 2009                                                                          13 Countries in Asia, South America, and Africa, including Kenya, Nigeria, Vietnam (does not name all 13)                                                                             171            1.33                                              NS                            NS                      GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} colorimetry, HPLC, UV                                                Yes                                         Yes
  Kaur et al,^[@zoi180102r60]^ 2016                                                                              Equatorial Guinea, Cambodia, Ghana, Nigeria, Rwanda, Tanzania                                                                                                                         10079          19.3 (1.6-37)                                     Random                        Mystery client, overt   HPLC, MS                                                                                                                     Yes                                         Yes
  Kaur et al,^[@zoi180102r61]^ 2008                                                                              Tanzania                                                                                                                                                                              304            12.2 (7.5-23.8)                                   Random                        NS                      Dissolution, HPLC                                                                                                            Yes                                         NS
  Kenyan Ministry of Public Health and Sanitation,^[@zoi180102r62]^ 2011                                         Kenya                                                                                                                                                                                 451            8.2                                               Survey                        Mystery client          GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} dissolution, other[^b^](#zoi180102t1n2){ref-type="table-fn"}         Yes                                         Yes
  Kenyan Ministry of Public Health and Sanitation,^[@zoi180102r63]^ 2012                                         Kenya                                                                                                                                                                                 496            3                                                 Survey                        Mystery client          GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} other[^b^](#zoi180102t1n2){ref-type="table-fn"}                      Yes                                         Yes
  Khin et al,^[@zoi180102r66]^ 2016                                                                              Myanmar                                                                                                                                                                               51             23.5                                              Random                        NS                      GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} dissolution, HPLC, other[^b^](#zoi180102t1n2){ref-type="table-fn"}   Yes                                         NS
  Lalani et al,^[@zoi180102r71]^ 2015                                                                            Afghanistan                                                                                                                                                                           134            26                                                Random                        Mystery client, overt   GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} dissolution, HPLC, UV                                                Yes                                         NS
  Lon et al,^[@zoi180102r74]^ 2006                                                                               Cambodia                                                                                                                                                                              451            27.1                                              Convenience                   Mystery client, overt   GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} HPLC                                                                 Yes                                         NS
  Maponga and Ondari,^[@zoi180102r75]^ 2003                                                                      Gabon, Ghana, Kenya, Mali, Mozambique, Sudan, Zimbabwe                                                                                                                                288            21.5                                              Convenience                   NS                      HPLC, UV, dissolution                                                                                                        Yes                                         Yes
  Newton et al,^[@zoi180102r79]^ 2001                                                                            Cambodia, Lao People's Democratic Republic, Myanmar, Thailand, Vietnam                                                                                                                104            38                                                Convenience                   NS                      Colorimetry, visual inspection                                                                                               No                                          NS
  Newton et al,^[@zoi180102r80]^ 2008                                                                            Vietnam, Cambodia, Lao People's Democratic Republic, Myanmar, Thailand                                                                                                                391            49.9                                              Random, convenience           NS                      Visual inspection, colorimetry, HPLC, MS                                                                                     Yes                                         Yes
  Ochekpe et al,^[@zoi180102r82]^ 2010                                                                           Nigeria                                                                                                                                                                               70             44.3                                              Random                        NS                      GPHF-Minilab[^a^](#zoi180102t1n1){ref-type="table-fn"}                                                                       Yes                                         Yes
  Ogwal-Okeng et al,^[@zoi180102r83]^ 1998                                                                       Uganda                                                                                                                                                                                88             59.1                                              Random                        Mystery client          HPLC                                                                                                                         Yes                                         NS
  Ogwal-Okeng et al,^[@zoi180102r84]^ 2003                                                                       Uganda                                                                                                                                                                                92             44.6                                              Random                        Mystery client          HPLC                                                                                                                         Yes                                         NS
  Onwujekwe et al,^[@zoi180102r86]^ 2009                                                                         Nigeria                                                                                                                                                                               225            26.67                                             Random                        Mystery client, overt   Dissolution, HPLC                                                                                                            Yes                                         NS
  Osei-Safo et al,^[@zoi180102r87]^ 2014                                                                         Ghana, Togo                                                                                                                                                                           124            75.8                                              Convenience                   Mystery client          Visual inspection, colorimetry, TLC, HPLC                                                                                    Yes                                         NS
  Phanouvong et al,^[@zoi180102r90]^ 2013b                                                                       Thailand                                                                                                                                                                              709            1                                                 Random                        Mystery client, overt   GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} dissolution, other[^b^](#zoi180102t1n2){ref-type="table-fn"}         Yes                                         NS
  Phanouvong et al,^[@zoi180102r91]^ (2013a)                                                                     Cambodia                                                                                                                                                                              374            12.3                                              Random                        Mystery client, overt   GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} dissolution, other[^b^](#zoi180102t1n2){ref-type="table-fn"}         Yes                                         NS
  Pribluda et al,^[@zoi180102r93]^ 2012                                                                          Bolivia, Brazil, Colombia, Ecuador, Guyana, Suriname, Venezuela                                                                                                                       1663           11.6                                              Convenience                   NS                      GPHF-Minilab[^a^](#zoi180102t1n1){ref-type="table-fn"}                                                                       Yes                                         NS
  Tabernero et al,^[@zoi180102r108]^ 2015                                                                        Lao People's Democratic Republic                                                                                                                                                      158            25.4                                              Random                        Mystery client          HPLC, MS, UV, visual inspection                                                                                              Yes                                         Yes
  Tipke et al,^[@zoi180102r110]^ 2008                                                                            Burkina Faso                                                                                                                                                                          77             41.6                                              Random, convenience           Mystery client          GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} UV                                                                   Yes                                         Yes
  Tivura et al,^[@zoi180102r111]^ 2016                                                                           Ghana                                                                                                                                                                                 254            35.4                                              Random                        Mystery client          HPLC, MS, UV                                                                                                                 Yes                                         NS
  Vijaykadga et al,^[@zoi180102r115]^ 2006                                                                       Thailand                                                                                                                                                                              369            11.39 (11.1-29.4)                                 Survey                        Overt                   GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} HPLC                                                                 Yes                                         NS
  Visser et al,^[@zoi180102r116]^ 2015                                                                           Gabon                                                                                                                                                                                 432            3.7                                               Random                        Mystery client          GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} HPLC, UV                                                             Yes                                         NS
  World Health Organization,^[@zoi180102r122]^ 2009                                                              Madagascar, Senegal, Uganda                                                                                                                                                           197            32.5                                              Convenience                   Mystery client          GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} other[^b^](#zoi180102t1n2){ref-type="table-fn"}                      Yes                                         NS
  World Health Organization,^[@zoi180102r123]^ 2011                                                              Cameroon, Ethiopia, Ghana, Kenya, Nigeria, Tanzania                                                                                                                                   267            28.5                                              Random                        NS                      GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} HPLC, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                Yes                                         Yes
  Yeung et al,^[@zoi180102r126]^ 2015                                                                            Cambodia                                                                                                                                                                              291            31.3 (25.8-50)                                    Random, survey                Mystery client, overt   HPLC, MS, UV                                                                                                                 Yes                                         NS
  **Antimalarials and Antibiotics**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Baratta et al,^[@zoi180102r36]^ 2012[^c^](#zoi180102t1n3){ref-type="table-fn"}                                 Congo, Ethiopia, India, Malawi, Central African Republic, Guinea Conakry, Uganda, Brazil, Guinea Bissau, Madagascar, Kenya, Angola, Rwanda, Cameroon, Chad                            221            52                                                NS                            NS                      HPLC, UV, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                                    Yes                                         Yes
  Bate et al,^[@zoi180102r42]^ 2010[^c^](#zoi180102t1n3){ref-type="table-fn"}                                    Ghana, Tanzania, Uganda, Nigeria, Angola, Zambia, Kenya, India, Thailand, China, Turkey, Russia, Brazil                                                                               2065           10.82 (7.3-14.2)                                  NS                            Mystery client          GPHF-Minilab[^a^](#zoi180102t1n1){ref-type="table-fn"}                                                                       Yes                                         NS
  Bruneton,^[@zoi180102r44]^ 1995[^c^](#zoi180102t1n3){ref-type="table-fn"}                                      Cameroon, Madagascar, Chad                                                                                                                                                            429            31.2                                              NS                            Mystery client          HPLC, TLC, UV, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                               Yes                                         Yes
  Central Drugs Standard Control Organization,^[@zoi180102r45]^ 2009[^c^](#zoi180102t1n3){ref-type="table-fn"}   India                                                                                                                                                                                 2976           0.1                                               Survey                        Mystery client          Visual inspection, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                           NS                                          NS
  Hajjou et al,^[@zoi180102r53]^ 2015[^c^](#zoi180102t1n3){ref-type="table-fn"}                                  Ghana, Ethiopia, Liberia, Kenya, Mozambique, Cambodia, Indonesia, Lao People's Democratic Republic, Myanmar, Philippines, Thailand, Vietnam, China, Colombia, Ecuador, Guyana, Peru   15063          5.6 (2.9-11.5)                                    Convenience                   NS                      GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} HPLC                                                                 Yes                                         Yes
  Hetzel et al,^[@zoi180102r55]^ 2014                                                                            Papua New Guinea                                                                                                                                                                      360            10.1                                              Survey, random, convenience   Overt                   HPLC, UV, MS                                                                                                                 Yes                                         NS
  Kaale et al,^[@zoi180102r58]^ 2016[^c^](#zoi180102t1n3){ref-type="table-fn"}                                   Tanzania                                                                                                                                                                              242            6.2                                               Random                        Mystery client          GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} HPLC                                                                 Yes                                         NS
  Khan et al,^[@zoi180102r65]^ 2011[^c^](#zoi180102t1n3){ref-type="table-fn"}                                    Cambodia                                                                                                                                                                              679            4.6                                               Random                        Mystery client          HPLC, dissolution                                                                                                            Yes                                         NS
  Khuluza et al,^[@zoi180102r67]^ 2017                                                                           Malawi                                                                                                                                                                                56             12.5                                              Random                        Mystery client, overt   GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} dissolution, other[^b^](#zoi180102t1n2){ref-type="table-fn"}         Yes                                         Yes
  Petersen et al,^[@zoi180102r89]^ 2017[^c^](#zoi180102t1n3){ref-type="table-fn"}                                Cameroon, Democratic Republic of the Congo, India, Ghana, Kenya, Nigeria, Uganda                                                                                                      869            2.4                                               Convenience                   Mystery client, overt   GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} dissolution, HPLC, other[^b^](#zoi180102t1n2){ref-type="table-fn"}   Yes                                         NS
  Pouillot et al,^[@zoi180102r92]^ 2008                                                                          Niger, Cameroon                                                                                                                                                                       153            45.75                                             Random                        Overt                   HPLC, UV, dissolution                                                                                                        Yes                                         NS
  Risha et al,^[@zoi180102r95]^ 2008[^c^](#zoi180102t1n3){ref-type="table-fn"}                                   Tanzania                                                                                                                                                                              1257           3.7                                               Convenience                   Overt                   GPHF-Minilab,[^a^](#zoi180102t1n1){ref-type="table-fn"} dissolution                                                          Yes                                         NS
  Seear et al,^[@zoi180102r99]^ 2011                                                                             India                                                                                                                                                                                 300            43                                                Random                        Overt                   HPLC, MS                                                                                                                     Yes                                         NS
  Shakoor et al,^[@zoi180102r100]^ 1997                                                                          Nigeria, Thailand                                                                                                                                                                     96             36.5 (36-40)                                      Random                        Mystery client          HPLC                                                                                                                         Yes                                         Yes
  Sheth et al,^[@zoi180102r101]^ 2007[^c^](#zoi180102t1n3){ref-type="table-fn"}                                  India                                                                                                                                                                                 2455           0.3                                               Convenience                   Mystery client          Visual inspection, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                           Yes                                         NS
  Stenson et al,^[@zoi180102r104]^ 1998                                                                          Lao People's Democratic Republic                                                                                                                                                      366            11.5 (3.3-46.2)                                   Random                        NS                      TLC, UV, colorimetry, HPLC, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                  Yes                                         NS
  Syhakhang,^[@zoi180102r106]^ 2002[^c^](#zoi180102t1n3){ref-type="table-fn"}                                    Lao People's Democratic Republic                                                                                                                                                      666            46                                                Random                        Mystery client          TLC, UV, colorimetry, HPLC, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                  Yes                                         NS
  Syhakhang et al,^[@zoi180102r107]^ 2004[^c^](#zoi180102t1n3){ref-type="table-fn"}                              Lao People's Democratic Republic                                                                                                                                                      300            5.33                                              Random                        Mystery client          Disintegration, HPLC, UV, colorimetry, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                       Yes                                         NS
  Taylor et al,^[@zoi180102r109]^ 2001[^c^](#zoi180102t1n3){ref-type="table-fn"}                                 Nigeria                                                                                                                                                                               581            48                                                Random                        Mystery client          HPLC                                                                                                                         Yes                                         NS
  Tshilumba et al,^[@zoi180102r112]^ 2015[^c^](#zoi180102t1n3){ref-type="table-fn"}                              Democratic Republic of Congo                                                                                                                                                          60             31.7                                              Convenience                   NS                      Visual inspection                                                                                                            NS                                          NS
  Uganda Medicines Transparency Alliance,^[@zoi180102r113]^ 2014                                                 Uganda                                                                                                                                                                                105            4.8                                               Random                        NS                      GPHF-Minilab[^a^](#zoi180102t1n1){ref-type="table-fn"}                                                                       Yes                                         Yes
  Wondemagegnehu,^[@zoi180102r120]^ 1999[^c^](#zoi180102t1n3){ref-type="table-fn"}                               Myanmar, Vietnam                                                                                                                                                                      500            11.2                                              Random                        Mystery client          Other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                                              Yes                                         NS
  **Other**[^c^](#zoi180102t1n3){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Antignac et al,^[@zoi180102r35]^ 2017                                                                          Benin, Burkina Faso, Congo, the Democratic Republic of Congo, Guinea, Côte d\'Ivoire, Mauritania, Niger, Senegal, Togo                                                                1530           16.3                                              Random                        Mystery client          MS, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                                          Yes                                         NS
  Bate et al,^[@zoi180102r38]^ 2013                                                                              Angola, Democratic Republic of the Congo, Egypt, Ethiopia, Ghana, Kenya, Nigeria, Rwanda, Tanzania, Uganda, Zambia, India, Thailand, China, Turkey, Russia, Brazil                    713            9.1 (3.9-16.6)                                    Random                        Mystery client          GPHF-Minilab[^a^](#zoi180102t1n1){ref-type="table-fn"}                                                                       Yes                                         NS
  Fotiou et al,^[@zoi180102r49]^ 2009                                                                            Thailand                                                                                                                                                                              139            23.02                                             Convenience                   Mystery client          HPLC, MS, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                                    Yes                                         Yes
  Hall,^[@zoi180102r54]^ 2016                                                                                    Bangladesh, Egypt, Cambodia, Kenya, India, Mexico, Nigeria, Pakistan, Peru, Viet Nam, Nigeria, Nepal, Pakistan, Bangladesh, Argentina, Indonesia, Peru, the Philippines, Kazakhstan   215            45                                                Random, convenience           NS                      Visual inspection, HPLC, UV                                                                                                  Yes                                         Yes
  Karikari-Boateng,^[@zoi180102r59]^ 2013                                                                        Ghana                                                                                                                                                                                 279            63.8                                              Survey                        Overt                   Other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                                              NS                                          Yes
  Kuwana and Sabartova,^[@zoi180102r69]^ 2017                                                                    Burkina Faso, Democratic Republic of the Congo, Nigeria, Rwanda, Zambia                                                                                                               126            0.8                                               Convenience                   NS                      Other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                                              NS                                          NS
  Laroche et al,^[@zoi180102r72]^ 2005                                                                           Mauritania                                                                                                                                                                            146            13.7 (8.8-20)                                     Random, Convenience           NS                      HPLC, disintegration, IR, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                    Yes                                         Yes
  Laserson et al,^[@zoi180102r73]^ 2001                                                                          Colombia, Estonia, India, Latvia, Russia, Vietnam                                                                                                                                     71             10                                                Convenience                   NS                      TLC, UV                                                                                                                      Yes                                         Yes
  Mbaziira et al,^[@zoi180102r76]^ 2015                                                                          Namibia                                                                                                                                                                               151            13.9                                              NS                            NS                      Other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                                              NS                                          NS
  Roy et al,^[@zoi180102r97]^ 1993                                                                               Bangladesh                                                                                                                                                                            53             30.2                                              Random                        NS                      HPLC, UV, disintegration, dissolution, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                       Yes                                         Yes
  Stanton et al,^[@zoi180102r102]^ 2012                                                                          Ghana                                                                                                                                                                                 101            89.1 (76.09-100)                                  Random                        Mystery client          HPLC                                                                                                                         Yes                                         NS
  Stanton et al,^[@zoi180102r103]^ 2014                                                                          India                                                                                                                                                                                 381            53.8                                              Convenience                   Mystery client          Other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                                              Yes                                         NS
  Suleman et al,^[@zoi180102r105]^ 2014                                                                          Ethiopia                                                                                                                                                                              106            45.3                                              Random                        Mystery client          HPLC, dissolution, visual inspection, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                        Yes                                         NS
  Wang et al,^[@zoi180102r119]^ 2015                                                                             8 Countries and 5 internet pharmacies: South Africa, United States, China, Ethiopia, Thailand, Lao People's Democratic Republic, Mexico, Nigeria                                      88             6.82                                              Random                        NS                      HPLC, UV, dissolution, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                       Yes                                         NS
  World Health Organization,^[@zoi180102r121]^ 2007                                                              Cameroon, Democratic Republic of the Congo, Kenya, Nigeria, Tanzania, Uganda, Zambia                                                                                                  394            1.8                                               Convenience                   NS                      Visual inspection, dissolution, disintegration, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                              Yes                                         Yes
  World Health Organization,^[@zoi180102r124]^ 2016                                                              Burkina Faso, Kenya, Madagascar, Nepal, Nigeria, Tajikistan, Tanzania, Uganda, Vietnam, Zimbabwe                                                                                      204            23                                                Convenience                   NS                      Visual inspection, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                           Yes                                         NS
  Yang et al,^[@zoi180102r125]^ 2004                                                                             Cambodia                                                                                                                                                                              96             92.7                                              Random                        Mystery client          Disintegration, dissolution, other[^b^](#zoi180102t1n2){ref-type="table-fn"}                                                 No                                          NS

Abbreviations: GPHF-Minilab, Global Pharma Health Fund-Minilab; HPLC, high-performance liquid chromatography; IR, infrared spectrometry; MS, mass spectrometry; NS, not specified; TLC, thin-layer chromatography; UV, ultraviolet and visible spectroscopy.

GPHF-Minilab involves visual inspection, disintegration, and TLC.

Other testing methods include infrared spectroscopy, uniformity of mass, microbial load, etc.

These studies examined the quality of medicines beyond antibiotics and antimalarials, such as acid blockers, antacids, anthelmintics, antianemics, antimycobacterials, antifungals, antihypertensives, anti-inflammatories, antiretrovirals, bronchodilators, erectile dysfunction drugs, diuretics, spasmolytics, and steroids.

![Reported National Prevalences of Substandard and Falsified Medicines\
Results of studies included in the meta-analysis. Multicountry studies that did not report country-specific data were not included. Subcategorical prevalence is delineated by color (blue, green, purple, and red as categories 1 through 4), and by color gradation, with a darker color representing a higher prevalence. Total number of samples tested for each country is presented as a black circle with the diameter of the circle increasing proportionally to samples tested. This map was generated using study data and the Microsoft Excel 2016 3D Mapping tool.](jamanetwopen-1-e181662-g003){#zoi180102f3}

[Table 2](#zoi180102t2){ref-type="table"} presents the summary statistics and weighted prevalence of the subcategorizations of 8 study characteristics in the meta-analysis. Statistical analysis of the association between the mean SF prevalence of each subcategorization and the overall prevalence (13.6%) found studies with smaller sample sizes to report significantly higher mean prevalence (sample size 50-99: mean prevalence, 34.4%; *P* = .001 and sample size 100-249: mean prevalence, 31%; *P* \< .001). Conversely, the prevalence of studies that used convenience sampling (7.1%; *P* = .001) or survey sampling (2.3%; *P* = .009) and those that analyzed samples with the Global Pharma Health Fund's Minilab, a mobile minilaboratory suitcase, were found to be significantly lower (7.7%; P \< .001) than the overall prevalence of 13.6%.

###### Prevalence of Substandard and Falsified Medicines by Study Characteristics

  Category                                                                                  Studies, No. (%)   Samples, No. (%)   Prevalence (95% CI)   *P* Value                                          
  ----------------------------------------------------------------------------------------- ------------------ ------------------ --------------------- -------------------------------------------------- --------------------------------------------------
  Sample size                                                                                                                                                                                              
  50-99                                                                                     17 (18)            1213 (1.8)         34.4 (23.2-45.6)      .001[^a^](#zoi180102t2n1){ref-type="table-fn"}     \<.001[^a^](#zoi180102t2n1){ref-type="table-fn"}
  100-249                                                                                   30 (31)            4625 (6.8)         31.0 (22.9-39.0)      \<.001[^a^](#zoi180102t2n1){ref-type="table-fn"}   \<.001[^a^](#zoi180102t2n1){ref-type="table-fn"}
  250-499                                                                                   25 (26)            8679 (12.8)        20.6 (13.6-27.5)      .05                                                .001[^a^](#zoi180102t2n1){ref-type="table-fn"}
  500-999                                                                                   10 (10)            6969 (10.3)        17.0 (6.2-27.8)       .50                                                .06
  1000-9999[^b^](#zoi180102t2n2){ref-type="table-fn"}                                       12 (13)            21 211 (31.3)      7.0 (3.7-10.3)        .001[^a^](#zoi180102t2n1){ref-type="table-fn"}     NA
  ≥10 000[^c^](#zoi180102t2n3){ref-type="table-fn"}                                         2 (2)              25 142 (37.1)      11.9 (0-32.7)         .79                                                NA
  Publication year                                                                                                                                                                                         
  2015-2017[^b^](#zoi180102t2n2){ref-type="table-fn"}                                       25 (26)            34 535 (50.9)      12.4 (9.0-15.9)       .50                                                NA
  2010-2014                                                                                 32 (33)            17 764 (26.2)      14.1 (8.9-19.4)       .85                                                .59
  2000-2009                                                                                 31 (32)            13 040 (19.2)      15.2 (8.3-22.0)       .67                                                .49
  \<2000                                                                                    8 (8)              2500 (3.7)         20.4 (12.7-28.0)      .13                                                .07
  Sampling method                                                                                                                                                                                          
  Random[^b^](#zoi180102t2n2){ref-type="table-fn"}                                          35 (37)            24 926 (36.7)      17.4 (14.3-20.4)      .06                                                NA
  Convenience                                                                               17 (18)            24 334 (35.9)      7.1 (4.9-9.2)         .001[^a^](#zoi180102t2n1){ref-type="table-fn"}     \<.001[^a^](#zoi180102t2n1){ref-type="table-fn"}
  Survey                                                                                    4 (4)              4292 (6.3)         2.3 (0-6.0)           .009[^a^](#zoi180102t2n1){ref-type="table-fn"}     \<.001[^a^](#zoi180102t2n1){ref-type="table-fn"}
  Combination (random, convenience, and survey)[^d^](#zoi180102t2n4){ref-type="table-fn"}   4 (4)              871 (1.3)          47.4 (30.0-64.8)      .03[^a^](#zoi180102t2n1){ref-type="table-fn"}      .002[^a^](#zoi180102t2n1){ref-type="table-fn"}
  Not specified                                                                             36 (38)            13 416 (19.8)      18.7 (18.7-18.7)      .09                                                .71
  Purchasing method                                                                                                                                                                                        
  Mystery client[^b^](#zoi180102t2n2){ref-type="table-fn"}                                  40 (42)            23 754 (35)        14.0 (9.0-19.0)       .89                                                NA
  Overt                                                                                     11 (12)            5252 (7.7)         12.8 (3.2-22.5)       .88                                                .84
  Mystery client and overt                                                                  11 (12)            13 435 (19.8)      19.0 (13.3-24.6)      .10                                                .20
  Not specified                                                                             34 (35)            25 398 (37.4)      10.1 (6.8-13.4)       .04[^a^](#zoi180102t2n1){ref-type="table-fn"}      .21
  Chemical analysis                                                                                                                                                                                        
  Chemical analysis                                                                         95 (99)            67 779 (99.9)      13.6 (11.0-16.3)      \>.99                                              
  1 Form of chemical analysis                                                               31 (32)            22 708 (33.5)      12.0 (7.1-16.8)       .50                                                .14
  2 Forms of chemical analysis                                                              15 (16)            28 857 (42.5)      12.8 (8.5-17.2)       .72                                                .19
  ≥3 Forms of chemical analysis[^b^](#zoi180102t2n2){ref-type="table-fn"}                   49 (51)            16 214 (23.9)      17.3 (12.3-22.3)      .16                                                NA
  Performed chemical and visual analysis                                                    48 (50)            41 747 (61.5)      8.8 (5.8-11.8)        .003[^a^](#zoi180102t2n1){ref-type="table-fn"}     
  Chemical testing method[^e^](#zoi180102t2n5){ref-type="table-fn"}                                                                                                                                        
  HPLC                                                                                      60 (63)            44 177 (65.1)      14.2 (10.8-17.7)      .73                                                
  Dissolution                                                                               32 (33)            10 118 (14.9)      12.3 (7.4-17.2)       .59                                                
  Disintegration                                                                            15 (16)            5222 (7.7)         16.0 (7.4-24.5)       .60                                                
  GPHF-Minilab                                                                              26 (27)            30 712 (45.3)      7.7 (5.5-9.9)         \<.001[^a^](#zoi180102t2n1){ref-type="table-fn"}   
  TLC                                                                                       13 (14)            4884 (7.2)         24.8 (14.6-35.0)      .05                                                
  UV spectrometry                                                                           26 (27)            8621 (12.7)        19.6 (13.6-25.5)      .06                                                
  Colorimetry                                                                               14 (15)            4287 (6.3)         24.0 (11.6-36.3)      .13                                                
  Mass spectrometry                                                                         10 (10)            15 239 (22.5)      18.9 (14.0-23.7)      .06                                                
  Other analyses                                                                            40 (42)            17 231 (25.4)      14.8 (9.7-20.0)       .66                                                
  Conflict of interest                                                                                                                                                                                     
  No discernable conflict of interest[^b^](#zoi180102t2n2){ref-type="table-fn"}             69 (72)            54 120 (79.8)      14.2 (11.1-17.4)      .71                                                NA
  Potential conflict of interest                                                            12 (13)            8769 (12.9)        9.3 (6.5-12.2)        .01[^a^](#zoi180102t2n1){ref-type="table-fn"}      .03[^a^](#zoi180102t2n1){ref-type="table-fn"}
  Unclear                                                                                   15 (16)            4950 (7.3)         14.4 (4.8-24.0)       .87                                                .97
  MEDQUARG score[^f^](#zoi180102t2n6){ref-type="table-fn"}                                                                                                                                                 
  ≥6[^g^](#zoi180102t2n7){ref-type="table-fn"}                                              53 (55)            34 077 (50.2)      15.9 (12.1-19.7)      .25                                                NA
  \<6                                                                                       43 (45)            33 762 (49.8)      10.9 (7.1-14.6)       .16                                                .07
  Total                                                                                     96 (100)           67 839 (100)       13.6 (11.0-16.3)                                                         *I*^2^ = 99.9%

Abbreviations: GPHF-Minilab, Global Pharma Health Fund Minilab; HPLC, high-performance liquid chromatography; MEDQUARG, Medical Quality Assessment Reporting Guidelines; NA, not applicable; TLC, thin-layer chromatography; UV, ultraviolet and visible spectroscopy.

*P* \< .05.

Categorical gold standard, as recommended by Newton et al.^[@zoi180102r16]^

Number of studies in the subcategory was too small to be used as the categorical gold standard.

Total samples for subcategorization was less than 1000; thus, results lack statistical rigor.

As some studies were in more than 1 category, further subcategories could not be compared.

Reported prevalence was not weighted by the MEDQUARG score.

Studies with a MEDQUARG score of 6 or greater were considered to have been reported with sufficient quality.

To further examine the association between methodological quality of the studies and the reported SF prevalence, we statistically compared the mean prevalence of SF medicines for each of the 8 subcategorizations with the gold standard for each study characteristic. Small sample sizes and less rigorous sampling methods resulted in significant differences from the categorical gold standard of larger sample sizes (7.0%) and randomized sampling (17.4%). The mean prevalence of studies with potential conflict of interest (9.3%) was also significantly lower than both the overall prevalence (13.6%; *P* = .01) and studies without discernable conflict of interest (14.2%; *P* = .03). Interestingly, the mean SF prevalence of studies with adequate reporting quality (MEDQUARG score ≥6; 15.9%) was 5% higher than studies with a lower quality score (10.9%) but not significantly so (*P* = .07).

A random-effects model was used to examine studies for heterogeneity and publication bias. Studies in the meta-analysis indicate large amounts of heterogeneity (*I*^2^ = 99.9%), and the regression test for funnel plot asymmetry indicates publication bias (*P* \< .001). A mixed-effects model was used to test for 8 different potential modifiers where sample size was found to be the only significant modifier (*P* = .04) (eAppendix 3 in the [Supplement](#note-ZOI180102-1-s){ref-type="supplementary-material"}).

Economic Evidence and Estimated Impact {#H2-3-ZOI180102}
--------------------------------------

Our search for economic impact estimates yielded 65 unique records with each citing 1 or more of 17 different estimates of the economic effect of SF medicines. Three of these estimates were found to be citation errors, 4 did not estimate total economic impact or market size, and the root sources of 2 were untraceable, resulting in 8 economic estimates.

eTable 3 in the [Supplement](#note-ZOI180102-1-s){ref-type="supplementary-material"} presents the original sources of the 8 economic estimates, primarily of market size, ranging from \$10 billion to \$200 billion annually (median, \$31.25 billion). Of the 8 estimates traced back to their origin,^[@zoi180102r5],[@zoi180102r128],[@zoi180102r129],[@zoi180102r130],[@zoi180102r131],[@zoi180102r132],[@zoi180102r133],[@zoi180102r134]^ many were old and based on crude calculations by authors without methodological disclosure. Four estimates came from reports from international or intergovernmental organizations but 3 did not note how the estimates were derived. Three estimates were introduced as a rough back-of-the-envelope calculation in a peer-reviewed journal and 2 sources were potentially partisan involving a moderator's guide from a think tank and a book.^[@zoi180102r129],[@zoi180102r134]^

Discussion {#H1-4-ZOI180102}
==========

Findings from this systematic review and meta-analysis reveal that 13.6% of essential medicines tested in LMICs failed quality analysis. The highest prevalence of poor-quality medicines was observed in Africa, where 18.7% of samples were substandard or falsified. Deficiencies in quality were more prevalent among antimalarials (19.1%) than antibiotics (12.4%), while further studies are needed to understand the quality profile of other essential medicines.

These findings are similar to the estimated prevalence from a 2017 report by the WHO^[@zoi180102r5]^ and consistent with ranges reported in other reviews.^[@zoi180102r3],[@zoi180102r20],[@zoi180102r21],[@zoi180102r22],[@zoi180102r23],[@zoi180102r24],[@zoi180102r25],[@zoi180102r26],[@zoi180102r27],[@zoi180102r28],[@zoi180102r29]^ All studies within these reviews that met our inclusion criteria were included in our review; the slight variance between our results and those of previous analyses is likely due to these reviews including studies with small sample sizes as well as the sheer amount of study heterogeneity.

This review identified a significant amount of study heterogeneity and potential issues of quality of the prevalence data reported in publications. This is a significant issue as poor-quality prevalence data affect analyses of the health and economic effects of SF medicines as well as crucial policy and regulatory efforts to address the issue.^[@zoi180102r6]^ Unfortunately, controversy over the role of industry in defining the problem of SF medicines has slowed global efforts to address this issue in recent decades.^[@zoi180102r6],[@zoi180102r14]^ The International Medical Products Anti-counterfeiting Taskforce (IMPACT), established by the WHO in 2006, disbanded over perceived industry connections, and intellectual property concerns waylaid the agreement on the definition of SF medical products.^[@zoi180102r135]^ Concerns that anticounterfeiting efforts could adversely affect the legitimate generic drug industry---essential for access to medicines in LMICs---have been central to the debate.^[@zoi180102r136]^ This dispute has distracted from the public health and socioeconomic consequences as well as efforts to accurately assess the scope of the issue. As a result, efforts have been disjointed, and numerous studies with small sample sizes that do not use rigorous randomization, collection, and analysis methods have been conducted.

This review also identifies a significant gap in the literature on the economic burden of SF medicines due to the poor-quality of reported economic estimates and limited focus, primarily on market size. Robust economic analysis capturing the broader economic burden of SF medicines, such as additional costs of treatment and productivity losses, is critical to understanding the extent of the problem, raising awareness, developing intervention strategies, and fostering change. Future economic research is important to inform efforts to combat the falsification of medications and should be conducted following rigorous economic methods.^[@zoi180102r137],[@zoi180102r138]^

As demonstrated in the results of our prevalence subgroup analysis, use of less rigorous research, analysis, and reporting methods is detrimental to efforts to assess the scope of the issue because of the number of biases they introduce.^[@zoi180102r5],[@zoi180102r16],[@zoi180102r139]^ Studies aiming to support policy development should therefore follow rigorous standards of sampling, analysis, reporting, and disclosure. While metrics such as MEDQUARG exist to guide in the reporting of studies of the prevalence of SF medicines, greater effort and emphasis need to be placed on researching and standardizing international sampling, collection, and analysis protocols.^[@zoi180102r5],[@zoi180102r16],[@zoi180102r139]^ Improving quality control and laboratory capacity in LMICs is also crucial as the GPHF-Minilab that is used in these settings in lieu of full pharmacopeial analysis has poor sensitivity to detect substandard medicines.^[@zoi180102r11],[@zoi180102r67],[@zoi180102r123],[@zoi180102r140]^ Furthermore, to ensure that these efforts bear fruit, greater transparency is needed in the disclosure of industry-related potential conflicts of interest. This heterogeneity in findings serves to caution against extrapolating SF prevalences to other regions and across medicine categories.

Countries with weak pharmaceutical governance and poor pharmacovigilance are at the greatest risk from SF medications.^[@zoi180102r6],[@zoi180102r141],[@zoi180102r142]^ Weak regulatory capacity to license manufacturers, ensure good manufacturing practices, and perform quality control encourages the illicit manufacture and distribution of SF medications.^[@zoi180102r142]^ Poor supply chain management and surveillance not only open the door to allow SF medicines to permeate the supply chain, but also cause stock-outs that drive patients to purchase medicines from unregulated markets.^[@zoi180102r142]^ Therefore, efforts to improve supply-chain management, surveillance, and regulatory capacity in LMICs are essential to reduce the threat of SF medicines. The successes of the Promoting the Quality of Medicines and the WHO prequalified drug programs demonstrate that these efforts can reduce the prevalence of SF medicines.^[@zoi180102r137]^

While the effects of SF medications disproportionately rest on LMICs, SF medicines originate from and are reported in every country worldwide.^[@zoi180102r6],[@zoi180102r142]^ The global nature of the medicine supply chain implies that weaknesses in any country in the supply chain affect all the countries downstream.^[@zoi180102r142],[@zoi180102r143],[@zoi180102r144]^ This threatens global health security by increasing transmission, morbidity, mortality, and antimicrobial resistance, highlighting the need for a unified global effort to address the issue.^[@zoi180102r142],[@zoi180102r143],[@zoi180102r144]^ In 2013, the WHO Global Surveillance and Monitoring System was launched to gather data, improve reporting, and strengthen regulatory capacity globally.^[@zoi180102r6]^ While this is an important first step, additional efforts to implement laws on drug quality and improve data sharing among stakeholders are essential to complement research and technical initiatives.^[@zoi180102r144]^ Nayyar et al^[@zoi180102r145]^ have called for an international convention on SF medicines, similar to the 1929 treaty that internationally criminalized counterfeit banknotes or the Framework Convention on Tobacco Control.^[@zoi180102r146],[@zoi180102r147]^ Such a convention could (1) accurately define SF medicines, (2) require signatory countries to enact national laws (and consequent prosecution penalties) criminalizing intentional manufacture, trafficking, or selling of SF medicines, (3) provide a legal and institutional framework on convergent medicine regulation, and (4) provide LMICs with financial and technical assistance to effectively join local and regional SF medicine regulatory networks. Without such concerted global effort, the global supply chain, and thereby every country within it, remains vulnerable to SF medicines.

Limitations {#H2-4-ZOI180102}
-----------

Systematic reviews are inherently limited by their search strategies, databases searched, and the inclusion and exclusion criteria selected.^[@zoi180102r148]^ To address this limitation, we ran 2 searches, performed a systematic reference review, and examined other pertinent database sources. Furthermore, as with all meta-analyses, ours is limited by the quality of the included studies and any biases they may contain.^[@zoi180102r148]^ As demonstrated by the high amount of heterogeneity, the summary statistics reported in this study reflect a wide range of studies and methods, and as a result are subject to various limitations. For studies involving multiple medicines and countries, only the total sample size was included in the prevalence calculations. It is therefore possible that the regional variation observed is explained by differences in sample size by medicine, or that the variation by medicines is explained by the geographic distribution of samples. Differences in study quality, sampling, or purchasing and collection method across regions and medicine categories may have also introduced bias. To control for these potential sources of bias, we selected studies that tested 50 or more samples and removed studies with very poor sampling methods or no description of study methods. To further ensure the rigor of our reported prevalence estimates, each study prevalence was weighted by sample size and a metric that assessed the quality of the reported studies. Quality analyses indicate that there is significant publication bias as well as a moderating effect of sample size, even after controlling for it, which demonstrates the significance of rigorous sampling methods. Finally, reported economic impact estimates are limited by the poor quality and large heterogeneity of available data. Despite these limitations, we believe we appropriately controlled for bias to the best of our ability and have identified and synthesized articles in a systematic and methodical manner.

Conclusions {#H1-5-ZOI180102}
===========

Our findings suggest that SF essential medicines are a substantial and understudied problem in LMICs with high estimated economic impact. Reducing their prevalence is imperative to the Global Health Security Agenda, reaching the United Nations Sustainable Development Goals, and global efforts to curb antimicrobial resistance.^[@zoi180102r1],[@zoi180102r149]^ Although the literature on prevalence continues to grow, methodological standards are needed to improve generalizability and facilitate comparison across studies. Precise, independent estimates are also needed to describe the health and economic effects of poor-quality medicines to build the evidence base for successful policy interventions to curb SF medicines in LMICs. Efforts to strengthen supply-chain management, surveillance, and regulatory capacity are essential to effectively control SF medicines. Globalization necessitates global coordination across national, regional, and sectoral stakeholders to improve the regulation, standardization, and surveillance of the quality of medicines worldwide.
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